-
Olutasidenib showed disease control in IDH1-mutated chondrosarcoma
Phase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
-
Short-course anti-TB therapy followed regression of reactivated focus
Case report of ICI-induced TB reactivation managed with short-course anti-TB therapy followed by continued checkpoint inhibitor monotherapy, suggesting personalized management alternatives to.
-
Isoniazid monoresistance and alopecia occurred together in one TB case
Severe alopecia developed in a 22-year-old woman with isoniazid-monoresistant tuberculosis after starting treatment. Hair regrowth occurred after discontinuing isoniazid, highlighting the.
-
Childhood adversity linked to higher treatment-resistant depression risk
Cohort study demonstrating association between adverse childhood experiences and treatment-resistant depression, independent of familial confounding factors.
-
FAERS data show post-marketing adverse event patterns with casimersen
Pharmacovigilance analysis of casimersen adverse event reporting patterns using FAERS database with characterization of preferred terms, organ systems, and time-to-onset distributions.
-
Echocardiography may help identify high-risk pregnancy-induced hypertension patients
Echocardiographic parameters independently predict adverse pregnancy outcomes in women aged 35+ with pregnancy-induced hypertension, with combined assessment achieving excellent discrimination.
-
Nine-month oral TB regimens showed durable three-year outcomes
Nine-month all-oral TB regimens show 89.5% durable three-year cure rates but persistent linezolid neuropathy affects 22.6% of patients, raising safety concerns.
-
FMT with immunotherapy showed activity in NSCLC and melanoma
Phase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.
